Abacus dx Announces Commercial Partnership with Response Biomedical in Australia & New Zealand’s Clinical Market Sector
Brisbane, 6th November 2024
Abacus dx is proud to announce its partnership with Response Biomedical, a global leader in rapid diagnostic solutions, to launch the innovative RAMP® 200 instrument in the Australian and New Zealand markets. This collaboration marks a significant milestone in enhancing point-of-care testing capabilities across the region.
The RAMP instrument, known for its exceptional speed, accuracy, and user-friendly design, is set to transform diagnostic practices by providing healthcare professionals with rapid and reliable results the RAMP instrument will support healthcare providers in delivering timely and informed patient care.
Key Features of the RAMP Instrument:
- Rapid Results: Provides accurate diagnostic results in under 15 minutes.
- High Sensitivity and Specificity: Ensures reliable detection of a wide range of biomarkers: NT-ProBNP, Myoglobin and D-Dimer.
- User-Friendly Interface: Designed for ease of use in various healthcare settings.
- Portable and Compact: Ideal for use in clinics, hospitals, and remote locations.
About Abacus dx:
Abacus dx distributes diagnostic pathology, medical research, and innovative laboratory equipment solutions to a range of healthcare practitioners. Our customers include private and public pathology laboratories, blood donor centres as well as universities, research institutes, biotechnology companies and veterinary laboratories.
At Abacus dx we consistently add value to our suppliers’ products through our unrivalled service provision and support. We are very proud to have grown to be the successful and award-winning company that we are today, having supported our customers with superior solutions for almost 60 years. Abacus dx is part of the Diploma Healthcare group, owned by Diploma PLC.
For enquiries and details on your local territory representative, please get in touch with Claire Chupin, Business Unit Manager, Abacus dx: [email protected].
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
